Sutro Biopharma Gestione

Gestione criteri di controllo 2/4

Sutro Biopharma Il CEO è Bill Newell, nominato in Jan2009, e ha un mandato di 15.83 anni. la retribuzione annua totale è $ 2.13M, composta da 32.2% di stipendio e 67.8% di bonus, comprese azioni e opzioni aziendali. possiede direttamente 0.41% delle azioni della società, per un valore di € 858.25K. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 1.8 anni e 5.4 anni.

Informazioni chiave

Bill Newell

Amministratore delegato

US$2.1m

Compenso totale

Percentuale dello stipendio del CEO	32.2%
Mandato del CEO	15.8yrs
Proprietà del CEO	0.4%
Durata media del management	1.8yrs
Durata media del Consiglio di amministrazione	5.4yrs

Aggiornamenti recenti sulla gestione

Recent updates

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di Bill Newell rispetto agli utili di Sutro Biopharma?
Data	Compenso totale	Stipendio	Guadagni aziendali
Sep 30 2024	n/a	n/a	-US$124m
Jun 30 2024	n/a	n/a	-US$124m
Mar 31 2024	n/a	n/a	-US$115m
Dec 31 2023	US$2m	US$687k	-US$107m
Sep 30 2023	n/a	n/a	-US$172m
Jun 30 2023	n/a	n/a	-US$143m
Mar 31 2023	n/a	n/a	-US$130m
Dec 31 2022	US$3m	US$663k	-US$119m
Sep 30 2022	n/a	n/a	-US$123m
Jun 30 2022	n/a	n/a	-US$134m
Mar 31 2022	n/a	n/a	-US$114m
Dec 31 2021	US$6m	US$625k	-US$106m
Sep 30 2021	n/a	n/a	-US$127m
Jun 30 2021	n/a	n/a	-US$79m
Mar 31 2021	n/a	n/a	-US$43m
Dec 31 2020	US$2m	US$554k	-US$32m
Sep 30 2020	n/a	n/a	US$13m
Jun 30 2020	n/a	n/a	-US$17m
Mar 31 2020	n/a	n/a	-US$61m
Dec 31 2019	US$4m	US$497k	-US$56m
Sep 30 2019	n/a	n/a	-US$42m
Jun 30 2019	n/a	n/a	-US$40m
Mar 31 2019	n/a	n/a	-US$38m
Dec 31 2018	US$9m	US$482k	-US$35m
Sep 30 2018	n/a	n/a	-US$49m
Jun 30 2018	n/a	n/a	-US$40m
Mar 31 2018	n/a	n/a	-US$30m
Dec 31 2017	US$703k	US$468k	-US$20m

Compensazione vs Mercato: La retribuzione totale di Bill ($USD 2.13M ) è superiore alla media delle aziende di dimensioni simili nel mercato German ($USD 852.77K ).

Compensazione vs guadagni: La retribuzione di Bill è stata coerente con le performance aziendali dell'ultimo anno.

AMMINISTRATORE DELEGATO

Bill Newell (66 yo)

15.8yrs

Mandato

US$2,129,980

Compensazione

Mr. William J. Newell, also known as Bill, J.D. has been the Chief Executive Officer and Director of Sutro Biopharma, Inc. since February 2009. He served as Independent Director at Vaxcyte, Inc. since Nove...

Gruppo dirigente

Nome	Posizione	Mandato	Compensazione	Proprietà
William Newell	CEO & Director	15.8yrs	US$2.13m	0.41% € 858.2k
Hans-Peter Gerber	Chief Scientific Officer	1.2yrs	US$1.63m	0.029% € 61.5k
Anne Borgman-Hagey	Chief Medical Officer	1.8yrs	US$2.34m	0.030% € 62.1k
Jane Chung	President & COO	less than a year	US$1.43m	0.066% € 138.3k
James Swartz	Founder	no data	Nessun dato	Nessun dato
Edward Albini	CFO & Secretary	11.8yrs	US$2.08m	0.13% € 272.1k
Venkatesh Srinivasan	Chief Technical Operations Officer	1.5yrs	Nessun dato	0.038% € 80.9k
David Pauling	General Counsel	3.7yrs	Nessun dato	Nessun dato
Linda Fitzpatrick	Chief People & Communications Officer	16.8yrs	US$1.30m	0.10% € 212.4k
Barbara Leyman	Chief Business Development Officer	less than a year	Nessun dato	Nessun dato
Regina Cheng	Vice President & Controller	no data	Nessun dato	Nessun dato

1.8yrs

Durata media

62yo

Età media

Gestione esperta: Il team dirigenziale di S09 non è considerato esperto (durata media 1.8 anni), il che suggerisce un nuovo team.

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
William Newell	CEO & Director	15.8yrs	US$2.13m	0.41% € 858.2k
Connie Matsui	Independent Chair of the Board	5.4yrs	US$173.11k	0% € 0
James Panek	Independent Director	4.8yrs	US$138.11k	0% € 0
John Freund	Independent Director	10.8yrs	US$138.11k	0.068% € 143.6k
Daniel Petree	Independent Director	15.3yrs	US$140.11k	0.027% € 57.2k
Trevor Hallam	Member of Scientific Advisory Board	1.8yrs	US$1.53m	0.12% € 255.8k
Carlos Paya	Chair of the Scientific Advisory Board	4.5yrs	Nessun dato	Nessun dato
Michael Dybbs	Independent Director	6.3yrs	US$133.11k	0% € 0
Joseph Lobacki	Independent Director	7.8yrs	US$152.11k	0% € 0
Lawrence Fong	Co-Chair of Clinical Advisory Board & Member of Scientific Advisory Board	no data	Nessun dato	Nessun dato
Lainie Martin	Member of the Clinical Advisory Board	4.5yrs	Nessun dato	Nessun dato
Heidi Hunter	Independent Director	3yrs	US$150.28k	0% € 0

5.4yrs

Durata media

66yo

Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di S09 sono considerati esperti (durata media dell'incarico 5.4 anni).

Sutro Biopharma Gestione

Gestione criteri di controllo 2/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

Sutro Biopharma Appoints Dr. Barbara Leyman as Chief Business Development Officer

Sutro Biopharma, Inc., Annual General Meeting, Jun 06, 2024

Sutro Biopharma, Inc Appoints Jane Chung as President and Chief Operating Officer

Sutro Biopharma, Inc. Appoints Hans Peter Gerber as Chief Scientific Officer

Chief Business Officer recently sold €67k worth of stock

Sutro Biopharma, Inc. Announces Departure of Arturo Molina as Chief Medical Officer

Recent updates

Third quarter 2024 earnings released: US$0.59 loss per share (vs US$0.81 loss in 3Q 2023)

Sutro Biopharma, Inc. Announces Initiation of the Registration-Enabling REFRaME-P1 Trial with Luvelta for Pediatric Patients with CBF/GLIS AML

Sutro Biopharma Highlights Next-Generation ADC Innovation and Near-Term Pipeline At Research Forum

Sutro Biopharma Announces Updated Data from Phase 1b Study of Luvelta in Combination with Bevacizumab at ESMO2024

Sutro Biopharma Announces Initiation of REFRaME-L1 Phase 2 Trial with Luvelta for Patients with Non-Small Cell Lung Cancer

Second quarter 2024 earnings released: US$0.59 loss per share (vs US$0.64 loss in 2Q 2023)

Sutro Biopharma Appoints Dr. Barbara Leyman as Chief Business Development Officer

First quarter 2024 earnings released: US$0.95 loss per share (vs US$0.85 loss in 1Q 2023)

Sutro Biopharma, Inc. Announces Initiation of Randomized Portion (Part 2) of REFRaME-O1 Trial

Sutro Biopharma, Inc., Annual General Meeting, Jun 06, 2024

Sutro Biopharma, Inc. has completed a Follow-on Equity Offering in the amount of $74.999998 million.

Sutro Biopharma, Inc. has filed a Follow-on Equity Offering in the amount of $74.999998 million.

Full year 2023 earnings released: US$1.78 loss per share (vs US$2.35 loss in FY 2022)

Sutro Biopharma Highlights Potential Multi-Cancer Opportunity for Luvelta, a FolRa-Targeting ADC

Sutro Biopharma, Inc. Announces New Positive Data from the Compassionate Use of Luveltamab Tazevibulin (luvelta) in Pediatric Patients with Relapsed/Refractory CBF/GLIS Presented at ASH 2023

Sutro Biopharma, Inc Appoints Jane Chung as President and Chief Operating Officer

Third quarter 2023 earnings released: US$0.81 loss per share (vs US$0.37 loss in 3Q 2022)

Sutro Biopharma Announces Presentation of Data for Luveltamab Tazevibulin (luvelta) from the Phase 1 Dose-Expansion Study in Endometrial Cancers At ESMO 2023

Sutro Biopharma, Inc. Appoints Hans Peter Gerber as Chief Scientific Officer

Chief Business Officer recently sold €67k worth of stock

Second quarter 2023 earnings released: US$0.64 loss per share (vs US$0.55 loss in 2Q 2022)

First quarter 2023 earnings released: US$0.85 loss per share (vs US$0.84 loss in 1Q 2022)

Full year 2022 earnings released: US$2.35 loss per share (vs US$2.29 loss in FY 2021)

Sutro Biopharma, Inc. Announces Results from Phase 1 Dose-Expansion Study of STRO-002

Sutro Biopharma, Inc. Announces Presentation of STRO-002 Data from the Compassionate Use Program in Pediatric Patients with Relapsed/Refractory CBF/GLIS AML at ASH 2022

Third quarter 2022 earnings released: US$0.37 loss per share (vs US$0.67 loss in 3Q 2021)

Sutro Biopharma, Inc. Announces Departure of Arturo Molina as Chief Medical Officer

Second quarter 2022 earnings released: US$0.55 loss per share (vs US$0.13 loss in 2Q 2021)

High number of new directors

Sutro Biopharma, Inc.(NasdaqGM:STRO) dropped from Russell 2000 Growth Index

High number of new directors

First quarter 2022 earnings released: US$0.84 loss per share (vs US$0.66 loss in 1Q 2021)

Sutro Biopharma, Inc., Annual General Meeting, Jun 06, 2022

Sutro Biopharma, Inc. Presents Nonclinical Data for Antibody-Drug Conjugate STRO-002 at the AACR Annual Meeting 2022

CEO & Director recently bought €71k worth of stock

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Sutro Biopharma Announces Interim Data from Dose-Expansion Cohort of STRO-002 Phase 1 Study for Patients with Advanced Ovarian Cancer

High number of new directors

Sutro Biopharma, Inc. Announces Company Kol Virtual Event to Provide Interim Dose Expansion Data for Antibody-Drug Conjugate Program Stro-002 for Treatment of Advanced Ovarian Cancer

Fred Hutchinson Cancer Research Center, in Partnership with Sutro Biopharma, to Present At American Society of Hematology Annual Meeting 2021

Third quarter 2021 earnings released: US$0.67 loss per share (vs US$0.47 profit in 3Q 2020)

Second quarter 2021 earnings released: US$0.13 loss per share (vs US$1.00 profit in 2Q 2020)

Sutro Biopharma Announces Additional Data for Dose-Escalation Phase 1 Study of STRO-002 to Be Presented At ASCO 2021

Forecast to breakeven in 2025

First quarter 2021 earnings released: US$6.61 loss per share (vs US$0.84 loss in 1Q 2020)

Full year 2020 earnings released: US$0.99 loss per share (vs US$2.43 loss in FY 2019)

Investor sentiment deteriorated over the past week

Sutro Biopharma Announces First Patient Dosed in the Dose-Expansion Study of STRO-002 in Patients with Ovarian Cancer

New 90-day high: €21.00

Investor sentiment improved over the past week

Sutro Biopharma Announces Encouraging Interim Data on STRO-002 Phase 1 Dose-Escalation Study for Patients with Ovarian Cancer

Market bids up stock over the past week

New 90-day high: €18.60

Sutro Biopharma Announces Appointment of Jon M. Wigginton to Board of Directors

Sutro Biopharma, Inc. Appoints Annie Chang as Head of Investor Relations

New 90-day high: €14.30

Market bids up stock over the past week

Revenue beats expectations

Third quarter 2020 earnings released: EPS US$0.46

New 90-day high: €11.10

New 90-day high - €10.00

Analisi delle retribuzioni degli amministratori delegati

AMMINISTRATORE DELEGATO

Mandato

Compensazione

Gruppo dirigente

Durata media

Età media

Membri del Consiglio di amministrazione